Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM versus LIQUAMAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM versus LIQUAMAR.
HEPARIN SODIUM vs LIQUAMAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin sodium potentiates the activity of antithrombin III, thereby inactivating thrombin and factor Xa, leading to inhibition of coagulation.
Liquamar (phenprocoumon) is a vitamin K antagonist that inhibits the synthesis of vitamin K-dependent clotting factors II, VII, IX, and X in the liver by blocking the reduction of vitamin K to its active hydroquinone form.
Intravenous: Initial bolus of 80 units/kg, then continuous infusion at 18 units/kg/h. Subcutaneous: 5000 units every 8-12 hours for prophylaxis.
Initial: 0.5-1 mg/kg IV (not to exceed 2 mg). Maintenance: 0.5-2 mg IV q8-12h based on INR.
None Documented
None Documented
The terminal elimination half-life of heparin is dose-dependent: approximately 30 minutes (low dose, e.g., 25 U/kg), 60 minutes (medium dose, 100 U/kg), and 150 minutes (high dose, 400 U/kg). Half-life increases with dose due to saturation of clearance mechanisms.
The terminal elimination half-life of phenprocoumon is approximately 5 to 7 days (range 3-10 days). This long half-life results in sustained anticoagulant effect over days, requiring careful monitoring and dose adjustments.
Heparin is cleared primarily via the reticuloendothelial system and liver, with minimal renal excretion. Unchanged heparin is not significantly excreted in urine. Biliary/fecal elimination is negligible.
Phenprocoumon is excreted primarily via renal elimination as metabolites (approximately 60-70% of the dose), with about 20% excreted in feces via biliary elimination. Less than 1% is excreted unchanged in urine.
Category A/B
Category C
Anticoagulant
Anticoagulant